About Lumenis Ltd.
Lumenis is Israel's largest medical device company with more than 1,000 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. In December 2006, a group led by a private equity consortium, Viola Partners and Ofer Hi-Tech Group, invested approximately $150 million in the Company.
Lumenis(R) is a registered trademark of Lumenis Ltd.;
VersaPulse(R) is a registered trademark of Lumenis Ltd.; PowerSuite(TM) is a trademark of Lumenis Ltd.
(1) 2007, Ehab A. Elzayat, Mostafa M. Elhilali, European Urology, Holmium Laser Enucleation of the Prostate (HoLEP): Long-Term Results, Reoperation Rate, and Possible Impact of the Learning Curve
(3) 2008, Kuntz, R. et al., Holmium Laser Enucleation of the Prostate versus Open Prostatectomy for Prostates Greater than 100 Grams: 5 - Year Follow Up Results of a Randomised Clinical Trial
2007, Matlaga, B. et al., Current Opinion in Urology, Holmium laser treatment of benign prostatic hyperplaisa: an update
(2) 2008, Peter J. Gilling, Tevita F. Aho, et al., European Urology, Holmium Laser Enucleation of the Prostate: Results at 6 Years
2007, Sascha A. Ahyai, et al., European Urology, Holmium Laser Enucleation versus Transurethral Resection of the Prostate: 3-Year Follow-Up Results of a Randomized Clinical Trial
|SOURCE Lumenis Ltd.|
Copyright©2008 PR Newswire.
All rights reserved